Aboligo
Antibody-oligonucleotide conjugates and custom conjugation services for life-science researchers
Highlights
- Young companyFounded 2024
- New on EvolcAdded 2026-11-09
About Aboligo
AbOliGo develops and manufactures antibody-oligonucleotide conjugates (AOCs) for multiplexed protein analysis, spatial biology, proteomics and single-cell workflows. It offers catalog products and custom conjugation services, including quantitative quality control and tailored labeling.
Product: Catalog AOCs and custom antibody-oligonucleotide conjugation, purification and quality-control services.
Jobs at Aboligo
Leadership
- Brian Carpenter · CEOSource: company website
- Ed Ralph · CTOSource: company website
More biotech & pharma companies
Abzena
Biologics and bioconjugates drug development and manufacturing services for biotech, academic and pharmaceutical organizationsNew on EvolcAcacia Pharma
Develops and commercializes hospital medicines for anesthesia, surgical, and oncology care teamsNew on EvolcAccord Healthcare
Generic, biosimilar and added-value medicines for hospital and retail pharmacies in more than 85 countriesNew on EvolcActimed Therapeutics
Clinical-stage drug developer targeting cancer cachexia and muscle wasting with S-pindolol benzoate in Phase 2New on EvolcActual Analytics
Home-cage behaviour monitoring systems that track individual rodents in social groups for preclinical research labsNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Frontend frameworks
- Next.jsHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- ReactMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Related technologyimplied by Next.js
- Tailwind CSSMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Page markupsoftware structure signature
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.
